Clinical trials: Heart Failure, Reduced Ejection Fraction
Heart Failure
A Research Study to Look at How Ziltivekimab Works Compared to Placebo in People With Heart Failure and Inflammation
This study will be done to see if ziltivekimab can be used to treat people living with heart failure and inflammation. Participants will either get ziltivekimab or placebo.
- Trial name
- HERMES (NCT05636176)
- Testing
- Ziltivekimab
- Where
- 1,013 sites in United States, Argentina and 44 more
- Volunteers
- 4,874 people
- Sponsor
- Novo Nordisk A/S
Heart Failure With Reduced Ejection Fraction
Home Outpatient Monitoring and Engagement to Predict HF Exacerbation
The HOME PREDICT HF study looks at new ways to predict hospitalizations for heart failure. We will use a set of devices at home and surveys to collect information about patient's health.
- Trial name
- Home Predict (NCT03479424)
- Testing
- Observational
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- University of California, San Francisco
Atrial Fibrillation (AF), Hart Failure
Heart Failure Biomarkers
Systemic inflammation is closely associated with the development and progression of heart failure (HF). The study assessed the fibrin/albumin (FAR) ratio, a very important biomarker, as a prognostic indicator of HE.
- Trial name
- BIOHF (NCT06616038)
- Testing
- Data collection
- Where
- 2 sites in Italy
- Volunteers
- 114 people
- Sponsor
- I.R.C.C.S Ospedale Galeazzi-Sant'Ambrogio
Heart Failure, Heart Failure With Reduced Ejection Fraction
Gender-Based Differences in Heart Failure Hospitalizations Among Patients With Heart Failure Treated With Spironolactone
Aldosterone antagonists or mineralocorticoid receptor antagonists (MRAs) are used as therapeutic agents for the management of HF with reduced ejection fraction (HFrEF).
- Conditions
- Heart Failure, Heart Failure With Reduced Ejection Fraction, Heart Failure NYHA Class II, Heart Failure NYHA Class III
- Trial name
- NCT06641284
- Testing
- Spironolactone
- Where
- Saudi Arabia
- Volunteers
- 509 people
- Sponsor
- Ahmad Abdullah Salawi
Heart Failure, Systolic, Heart Failure, Diastolic
Associations Between the Microbiome, Skeletal Muscle Perfusion, and Fitness Status
The purpose of the study is to determine associations between fitness status, bacteria in the mouth, and the blood flow to muscle.
- Conditions
- Heart Failure, Systolic, Heart Failure, Diastolic, Peripheral Arterial Disease, Overweight and Obesity
- Trial name
- NCT06009276
- Where
- United States
- Volunteers
- 70 people
- Sponsor
- University of Virginia
Chronic Kidney Diseases, Heart Failure With Reduced Ejection Fraction
Lokelma for RAAS Maximisation in CKD & Heart Failure.
Background: CKD in patients with heart failure (HF) is common and associated with poor prognosis. Despite evidence of benefit with Renin-Angiotensin-Aldosterone-System inhibitor (RAASi) agents, they are avoided due to fear of…
- Conditions
- Chronic Kidney Diseases, Heart Failure With Reduced Ejection Fraction, Hyperkalemia, ACE Inhibitor Induced Hyperkalaemia
- Trial name
- LIFT (NCT05004363)
- Testing
- Lokelma Oral Product
- Where
- United Kingdom
- Volunteers
- 112 people
- Sponsor
- St George's, University of London
Acute Congestive Heart Failure, Heart Failure With Reduced Ejection Fraction
Circulating RNAs in Acute Congestive Heart Failure
The purpose of this American Heart Association-funded and NIH-funded study is to examine circulating RNAs in the acute CHF setting, how they change with decongestive therapy, and their function in vitro and in vivo.
- Conditions
- Acute Congestive Heart Failure, Heart Failure With Reduced Ejection Fraction, Heart Failure With Normal Ejection Fraction
- Trial name
- CRUCiAL (NCT03345446)
- Testing
- Cardiac MRI
- Where
- 3 sites in United States
- Volunteers
- 200 people
- Sponsor
- Massachusetts General Hospital
Heart Failure With Reduced Ejection Fraction
Digital Solutions in Heart Therapy (DIGNITY)
This study aims to assess the safety and effectiveness of telemedicine guided strategy on guideline-directed medical therapy (GDMT) optimization in hospitalized patients with heart failure in comparison to usual care in…
- Trial name
- DIGNITY - HF (NCT06942221)
- Testing
- usual care, guideline-directed medical therapy
- Where
- Switzerland
- Volunteers
- 140 people
- Sponsor
- University Hospital, Basel, Switzerland
Heart Failure With Moderately Reduced Ejection Fraction
The Effect of Sacubitril/Valsartan Versus Ramipril on Left Ventricular Function and Remodeling in Patients With Ischemic Heart Failure With Mid-range Ejection Fraction
Heart failure with moderately reduced ejection fraction (HFmrEF) is a frequent disease associated with significant morbidity and mortality and therefore requires effective therapies that may improve clinical outcomes.
- Trial name
- CRACOVIA-HF (NCT05508035)
- Testing
- Sacubitril / Valsartan, Ramipril
- Where
- Poland
- Volunteers
- 488 people
- Sponsor
- John Paul II Hospital, Krakow
Heart Failure With Reduced Ejection Fraction
EVOlocumab in Stable Heart Failure With Reduced Ejection Fraction of Ischemic Etiology: EVO-HF Pilot
Evolocumab has been able to reduce the incidence of cardiovascular events in patients that had at least one cardiovascular risk factor [28].
- Trial name
- EVO-HF (NCT03791593)
- Testing
- Evolocumab
- Where
- 3 sites in Spain
- Volunteers
- 46 people
- Sponsor
- Fundació Institut Germans Trias i Pujol
Combined Pre- and Post-capillary Pulmonary Hypertension, CpcPH
Clinical Trial to Evaluate the Efficacy and Safety in Concomitant Administration of Macitentan and Dapagliflozin in Patients With Heart Failure With Mildly Reduced and Preserved Ejection Fraction (HFmrEF and HFpEF) and Combined Pre- and Post-capillary Pulmonary Hypertension (CpcPH)
This clinical trial will evaluate whether combination therapy with Dapagliflozin + Macitentan improves outcomes compared to Dapagliflozin + placebo in patients with combined pre- and post-capillary pulmonary hypertension (CpcPH).
- Conditions
- Combined Pre- and Post-capillary Pulmonary Hypertension, CpcPH, HFmrEF, HFpEF
- Trial name
- NCT07147114
- Testing
- Combination therapy, Monotherapy
- Where
- 15 sites in South Korea
- Volunteers
- 64 people
- Sponsor
- Gachon University Gil Medical Center
Chronic Heart Failure With Reduced Ejection Fraction
Omecamtiv Mecarbil Post-trial Access Study
The primary objective of this study is to provide access to omecamtiv mecarbil for participants who have completed GALACTIC-HF 20110203.
- Trial name
- NCT04464525
- Testing
- Omecamtiv mecarbil
- Sponsor
- Cytokinetics
Congestive Heart Failure
Blood Volume and Hemodynamic Analysis in Patients With Chronic Heart Failure
The primary hypothesis is that patients with HFREF (heart failure with reduced ejection fraction) will demonstrate a markedly expanded intravascular volume which will correlate with elevated right heart hemodynamics and increased…
- Trial name
- NCT02120014
- Testing
- blood volume measurement, venous plethysmography
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- Mayo Clinic
HFrEF - Heart Failure With Reduced Ejection Fraction, Myocardial Infarction (MI)
Vericiguat for Heart Failure With Reduced Ejection Fraction After Myocardial Infarction
The effects of vericiguat on cardiac remodeling in patients with chronic stable heart failure after myocardial infarction have not been reported.
- Trial name
- HFrEF (NCT06717204)
- Testing
- Vericiguat Oral Tablet [Verquvo], Prescription Drugs
- Where
- 3 sites in China
- Volunteers
- 210 people
- Sponsor
- Qilu Hospital of Shandong University
Heart Failure, Systolic
Robotic-assisted Exercise Training in Heart Failure With Reduced Ejection Fraction
This study will address the challenging task of remobilizing patients with advanced chronic lung or heart failure in a functional New York Heart Association class III-IV by using an externally physically-supported exosuit…
- Trial name
- NCT05278429
- Testing
- Myosuit robotic device
- Where
- Germany
- Volunteers
- 30 people
- Sponsor
- German Heart Institute
Adherence, Medication, Adherence, Treatment
Visualization of the Effects of Guideline-directed Medical Therapy (GDMT) on Improving Adherence and Quality of Life in Heart Failure With Reduced Ejection Fraction (HFrEF)
Heart failure with reduced ejection fraction (HFrEF) remains a major public health challenge with substantial morbidity and mortality despite the availability of effective guideline-directed medical therapy (GDMT).
- Conditions
- Adherence, Medication, Adherence, Treatment, Heart Failure
- Trial name
- VISUALIZE-PRO (NCT07505511)
- Testing
- Intervention: Visual Adherence Support (VISUALIZE-Pro)
- Volunteers
- 100 people
- Sponsor
- University of Giessen
Heart Failure, Left Bundle-Branch Block
Conventional Biventricular Versus Left Bundle Branch Pacing on Outcomes in Heart Failure Patients
Heart failure (HF) is the most common nosology encountered in clinical practice. Its incidence and prevalence increase exponentially with increasing age and it is associated with increased mortality, more frequent hospitalization…
- Conditions
- Heart Failure, Left Bundle-Branch Block, Ischemic Cardiomyopathy, Non-ischemic Dilated Cardiomyopathy
- Trial name
- RECOVER-HF (NCT05769036)
- Testing
- Implantation of Cardioverter-defibrillator with a Resynchronization Function Using Biventricular Pacing, Implantation of Cardioverter-defibrillator with a Resynchronization Function Using Left Bundle Branch Pacing
- Where
- Russia
- Volunteers
- 60 people
- Sponsor
- Tomsk National Research Medical Center of the Russian Academy of Sciences
Chronic Heart Failure With Reduced Ejection Fraction
An Observational Study Called ROVER to Learn More About How Well Vericiguat Works in People Who Were Newly Treated With Vericiguat in Routine Medical Care in Germany
This is an observational study in which data already collected from people treated with vericiguat are studied. In observational studies, only observations are made without participants receiving any advice or any changes to…
- Trial name
- ROVER (NCT06486844)
- Testing
- Vericiguat (Verquvo, BAY1021189)
- Where
- Germany
- Volunteers
- 500 people
- Sponsor
- Bayer
Heart Failure
REGN5381 in Adult Participants With Heart Failure With Reduced Ejection Fraction
This study is researching an experimental drug called REGN5381 (called "study drug"). The study is focused on patients with heart failure with reduced ejection fraction (ie, the heart is not functioning as well as it should).
- Trial name
- NATRIX-BNP (NCT06237309)
- Testing
- REGN5381
- Where
- 44 sites in United States, Belgium and 10 more
- Volunteers
- 89 people
- Sponsor
- Regeneron Pharmaceuticals
Chronic Heart Failure, Heart Failure With Reduced Ejection Fraction (HFrEF)
Yiqi Fumai Lyophilized Injection for Chronic Heart Failure Caused by Coronary Heart Disease
This study will evaluate whether adding Yiqi Fumai lyophilized injection to stable guideline-directed treatment improves symptoms, physical limitations, and NT-proBNP in adults with stable chronic heart failure caused by coronary…
- Conditions
- Chronic Heart Failure, Heart Failure With Reduced Ejection Fraction (HFrEF), Coronary Heart Disease (CHD)
- Trial name
- NCT07803471
- Testing
- Yiqi Fumai Lyophilized Injection(YQFM), Stable Guideline-Directed Medical Therapy
- Where
- 4 sites in China
- Volunteers
- 100 people
- Sponsor
- China Academy of Chinese Medical Sciences